PEAR
Pear Therapeutics, Inc. [PEAR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PEAR Stock Summary
In the News
PEAR Financial details
Company Rating
Strong Buy
Market Cap
4.09M
Income
24.78M
Revenue
12.69M
Book val./share
0.22
Cash/share
0.43
Dividend
-
Dividend %
-
Employees
200
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
0.16
Forward P/E
-
PEG
-0.01
P/S
0.32
P/B
0.13
P/C
-
P/FCF
-0.03
Quick Ratio
1.34
Current Ratio
1.48
Debt / Equity
1.23
LT Debt / Equity
0.27
-
-
EPS (TTM)
0.17
EPS next Y
-
EPS next Q
-
EPS this Y
-5.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-37.18%
EPS Q/Q
-184%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
58.62%
Inst Trans
1%
ROA
26%
ROE
43%
ROC
-2.7%
Gross Margin
36%
Oper. Margin
-972%
Profit Margin
195%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.009-6.74
52W High
-
52W Low
-
RSI
-
Rel Volume
6.57
Avg Volume
10.09M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.519904
-
-
Volatility
0.01%, 0.01%
Prev Close
-
Price
-
Change
-
PEAR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.24 | 0.07 | 0.04 | 0.09 | |
| Net income per share | 0.09 | -0.73 | -0.18 | -0.17 | |
| Operating cash flow per share | -0.27 | -0.49 | -0.96 | -0.82 | |
| Free cash flow per share | -0.27 | -0.52 | -1 | -0.85 | |
| Cash per share | 0.76 | 0.9 | 1.54 | 0.43 | |
| Book value per share | -0.48 | -1.32 | 0.8 | 0.22 | |
| Tangible book value per share | -0.48 | -1.32 | 0.8 | 0.22 | |
| Share holders equity per share | -0.48 | -1.32 | 0.8 | 0.22 | |
| Interest debt per share | 0.11 | 0.21 | 0.2 | 0.3 | |
| Market cap | 1.38B | 1.38B | 702.64M | 163.67M | |
| Enterprise value | 1.37B | 1.29B | 560.06M | 152.98M | |
| P/E ratio | 111.21 | -13.7 | -34.62 | -6.89 | |
| Price to sales ratio | 42.32 | 146.84 | 166.98 | 12.89 | |
| POCF ratio | -37.65 | -20.3 | -6.44 | -1.44 | |
| PFCF ratio | -37.37 | -19.19 | -6.18 | -1.39 | |
| P/B Ratio | -20.87 | -7.56 | 7.77 | 5.35 | |
| PTB ratio | -20.87 | -7.56 | 7.77 | 5.35 | |
| EV to sales | 41.94 | 137.83 | 133.09 | 12.05 | |
| Enterprise value over EBITDA | -26.41 | -17.2 | -3.67 | -0.9 | |
| EV to operating cash flow | -37.32 | -19.05 | -5.14 | -1.34 | |
| EV to free cash flow | -37.04 | -18.02 | -4.93 | -1.3 | |
| Earnings yield | 0.01 | -0.07 | -0.03 | -0.15 | |
| Free cash flow yield | -0.03 | -0.05 | -0.16 | -0.72 | |
| Debt to equity | -0.23 | -0.14 | 0.3 | 1.23 | |
| Debt to assets | 0.14 | 0.2 | 0.14 | 0.4 | |
| Net debt to EBITDA | 0.24 | 1.12 | 0.94 | 0.06 | |
| Current ratio | 6.26 | 3.1 | 3.93 | 1.48 | |
| Interest coverage | 0 | -29.92 | 25.5 | -31.69 | |
| Income quality | 3.92 | 0.7 | 1.67 | 1.51 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.1 | 2.99 | 8.8 | 3.81 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.06 | 0.04 | 0.03 | |
| Capex to revenue | -0.01 | -0.42 | -1.1 | -0.27 | |
| Capex to depreciation | -1.34 | -9.05 | -2.06 | -0.61 | |
| Stock based compensation to revenue | 0.04 | 0.96 | 0.91 | 1.07 | |
| Graham number | 0.98 | 4.66 | 1.79 | 0.92 | |
| ROIC | -0.82 | 0.51 | -0.28 | -0.5 | |
| Return on tangible assets | 0.11 | -0.76 | -0.1 | -0.25 | |
| Graham Net | -0.51 | -1.38 | 0.61 | 0 | |
| Working capital | 89.88M | 85.37M | 138.08M | 23.52M | |
| Tangible asset value | -66.04M | -182.31M | 90.43M | 30.59M | |
| Net current asset value | -68.76M | -188.62M | 78.52M | 8.42M | |
| Invested capital | -0.23 | -0.14 | 0.3 | 1.23 | |
| Average receivables | 0 | 632.5K | 1.03M | 4.37M | |
| Average payables | 0 | 3.6M | 3.16M | 2.53M | |
| Average inventory | 0 | 0 | 0 | 34.5K | |
| Days sales outstanding | 11.3 | 10 | 155.61 | 199.64 | |
| Days payables outstanding | 986.01 | 957.33 | 125.97 | 145.56 | |
| Days of inventory on hand | 0 | 0 | 0 | 3.08 | |
| Receivables turnover | 32.3 | 36.51 | 2.35 | 1.83 | |
| Payables turnover | 0.37 | 0.38 | 2.9 | 2.51 | |
| Inventory turnover | 0 | 0 | 0 | 118.58 | |
| ROE | -0.19 | 0.55 | -0.22 | -0.78 | |
| Capex per share | 0 | -0.03 | -0.04 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.03 | 0.02 | 0.02 | 0.03 | 0.02 | |
| Net income per share | -0.67 | -0.09 | 0.3 | -0.25 | 0.21 | |
| Operating cash flow per share | -0.79 | -0.27 | -0.2 | -0.17 | -0.18 | |
| Free cash flow per share | -0.79 | -0.27 | -0.21 | -0.17 | -0.18 | |
| Cash per share | 1.27 | 1 | 0.73 | 0.6 | 0.43 | |
| Book value per share | 0.66 | 0.5 | 0.54 | 0.38 | 0.22 | |
| Tangible book value per share | 0.66 | 0.5 | 0.54 | 0.38 | 0.22 | |
| Share holders equity per share | 0.66 | 0.5 | 0.54 | 0.38 | 0.22 | |
| Interest debt per share | 0.03 | 0.29 | 0.26 | 0.28 | 0.29 | |
| Market cap | 854.35M | 696.15M | 227.03M | 283.47M | 163.67M | |
| Enterprise value | 685.46M | 645.34M | 205.24M | 261.85M | 152.98M | |
| P/E ratio | -2.32 | -13.41 | 1.3 | -2.04 | 1.42 | |
| Price to sales ratio | 203.03 | 253.24 | 68.86 | 69.43 | 63.81 | |
| POCF ratio | -7.84 | -18.96 | -7.66 | -12.18 | -6.74 | |
| PFCF ratio | -7.84 | -18.71 | -7.33 | -11.89 | -6.46 | |
| P/B Ratio | 9.45 | 10.02 | 2.87 | 5.43 | 5.35 | |
| PTB ratio | 9.45 | 10.02 | 2.87 | 5.43 | 5.35 | |
| EV to sales | 162.89 | 234.76 | 62.25 | 64.13 | 59.64 | |
| Enterprise value over EBITDA | -11.24 | -14.23 | -2.93 | -12.06 | -4.74 | |
| EV to operating cash flow | -6.29 | -17.58 | -6.93 | -11.25 | -6.3 | |
| EV to free cash flow | -6.29 | -17.34 | -6.63 | -10.98 | -6.03 | |
| Earnings yield | -0.11 | -0.02 | 0.19 | -0.12 | 0.18 | |
| Free cash flow yield | -0.13 | -0.05 | -0.14 | -0.08 | -0.15 | |
| Debt to equity | 0.01 | 0.56 | 0.49 | 0.73 | 1.23 | |
| Debt to assets | 0 | 0.22 | 0.27 | 0.32 | 0.4 | |
| Net debt to EBITDA | 2.77 | 1.12 | 0.31 | 1 | 0.33 | |
| Current ratio | 3.93 | 3.24 | 2.57 | 2.05 | 1.48 | |
| Interest coverage | -8.26 | -34.19 | -95.69 | -41.16 | -8.99 | |
| Income quality | 1.67 | 1.54 | -5.43 | 0.76 | 0.92 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 8.8 | 4.83 | 3.86 | 2.54 | 4.66 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0.04 | 0.02 | 0.04 | |
| Capex to revenue | 0 | -0.18 | -0.4 | -0.14 | -0.42 | |
| Capex to depreciation | 0 | -0.39 | -0.94 | -0.39 | -0.7 | |
| Stock based compensation to revenue | 0 | 1.06 | 1.03 | 0.87 | 1.44 | |
| Graham number | 3.14 | 1.03 | 1.89 | 1.46 | 1.02 | |
| ROIC | -0.53 | -0.16 | -2.05 | -0.3 | 0.41 | |
| Return on tangible assets | -0.47 | -0.08 | 0.31 | -0.29 | 0.3 | |
| Graham Net | 0.5 | 0.28 | 0.32 | 0.16 | 0 | |
| Working capital | 138.08M | 103.67M | 73.9M | 50.71M | 23.52M | |
| Tangible asset value | 90.43M | 69.51M | 79.04M | 52.25M | 30.59M | |
| Net current asset value | 78.52M | 47.47M | 57.39M | 31.38M | 8.42M | |
| Invested capital | 0.01 | 0.56 | 0.49 | 0.73 | 1.23 | |
| Average receivables | 1.06M | 2.96M | 4.75M | 6.28M | 7.06M | |
| Average payables | 2.45M | 2.78M | 2.9M | 1.58M | 2.19M | |
| Average inventory | 0 | 0 | 33K | 70K | 71.5K | |
| Days sales outstanding | 38.37 | 135.25 | 146.78 | 158.33 | 243.61 | |
| Days payables outstanding | 31.06 | 227.89 | 76.47 | 39.59 | 168.29 | |
| Days of inventory on hand | 0 | 0 | 2.47 | 2.61 | 3.56 | |
| Receivables turnover | 2.35 | 0.67 | 0.61 | 0.57 | 0.37 | |
| Payables turnover | 2.9 | 0.39 | 1.18 | 2.27 | 0.53 | |
| Inventory turnover | 0 | 0 | 36.38 | 34.53 | 25.29 | |
| ROE | -1.02 | -0.19 | 0.55 | -0.67 | 0.94 | |
| Capex per share | 0 | 0 | -0.01 | 0 | -0.01 |
PEAR Frequently Asked Questions
What is Pear Therapeutics, Inc. stock symbol ?
Pear Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol PEAR
What is Pear Therapeutics, Inc. stock quote today ?
Pear Therapeutics, Inc. stock price is $- today.
Is Pear Therapeutics, Inc. stock public?
Yes, Pear Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 10.09M
- Market Capitalization 4.09M
- Employee 200
- CEO Mr. Christopher D. T. Guiffre J.D., M.B.A., MBA
- Headquarters Boston,MA,US
- IPO Date 2021-03-31
-
Website
https://peartherapeutics.com 
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
